188
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Isolation and Identification of Escherichia coli and Klebsiella pneumoniae Strains Resistant to the Oxyimino-Cephalosporins and the Monobactam by Production of GES Type Extended Spectrum Bêta-Lactamase (ESBL) at Saint Camille Hospital Center in Ouagadougou, Burkina Faso

ORCID Icon, , , ORCID Icon, & ORCID Icon
Pages 3191-3204 | Published online: 20 Jun 2022

References

  • Amana MD, Jacob ZK, Boukaré ZE, Jihad MO, Marie BA, Mondher EJ. Resistances to the oxyimino-cephalosporins by CTX-M-15 producing Klebsiella isolated from the urines samples of patients in the University Hospital Complex Paediatric Charles De Gaulle (CHUP-CDG) of Ouagadougou in Burkina Faso. J Asian Sci Res. 2013;3(9):882–890.
  • Struelens M. Résistance bactérienne par β-lactamases à spectre étendu: implications pour le réanimateur Extended spectrum β -lactamases mediated bacterial resistance: implications for the intensivist [Extended spectrum β-lactamase mediated bacterial resistance: implications for the resuscitator extended spectrum β-lactamases mediated bacterial resistance: implications for the intensivist]. Réanimation. 2006;15:205–213. French. doi:10.1016/j.reaurg.2006.03.006
  • Ahmadi M, Ranjbar R, Behzadi P, Mohammadian T. Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella pneumoniae. Expert Rev Anti Infect Ther. 2022;20(3):463–472. doi:10.1080/14787210.2022.1990040
  • Ouedraogo A. Prévalence, circulation et caractérisation des bactéries multirésistantes au Burkina Faso To cite this version: HAL Id: tel-01476152 Spécialité: Biologie Santé [Prevalence, circulation and characterization of multidrug-resistant bacteria in Burkina Faso To cite this version: HAL Id: tel-01476152 Specialty: Biology Health]. 2017. French.
  • Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018;2015. doi:10.1093/jac/dky027
  • Moini AS, Soltani B, Ardakani AT, Moravveji A, Rezaei MH, Namazi M. Multidrug-resistant Escherichia coli and Klebsiella pneumoniae isolated from patients in Kashan, Iran. Jundishapur J Microbiol. 2015;8(10). doi:10.5812/jjm.27517
  • Behzadi P, Urbán E, Matuz M, Benkő R, Gajdács M. The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol. 2020;1323:35–69. doi:10.1007/5584_2020_566
  • Ahmad A, Care CB. Nosocomial infections and their control strategies. Asian Pac J Trop Biomed. 2015;5:3–8.
  • Philippon A. Les bêta-lactamases à spectre élargi ou étendu (BLSE) [Extended or broad spectrum beta-lactamases (ESBL)]. Immuno Analyse Biol Spécialisée. 2013;28(5):287–296. French. doi:10.1016/j.immbio.2013.04.006
  • Vodovar D, Marcadé G, Raskine L, Malissin I, Mégarbane B. Entérobactéries productrices de bêta-lactamases à spectre élargi: épidémiologie, facteurs de risque et mesures de prévention [Extended-spectrum beta-lactamase-producing Enterobacteriaceae: epidemiology, risk factors and prevention measures]. La Rev Médecine Interne. 2013;34(11):687–693. French. doi:10.1016/j.revmed.2012.10.365
  • Naas T, Poirel L, Nordmann P. Minor extended-spectrum β-lactamases. Clin Microbiol Infect. 2008;14:42–52. doi:10.1111/j.1469-0691.2007.01861.x
  • Bradford PA. Extended-spectrum ␤ -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. ClinMicrobiol Rev. 2001;14(4):933–951. doi:10.1128/CMR.14.4.933
  • Dashti AA, Jadaon MM, Abdulsamad AM, Dashti HM. Heat treatment of bacteria: a simple method of DNA extraction for molecular techniques. Kuwait Med J. 2009;41(2):117–122.
  • Moubareck C, Bre S, Conroy M, Courvalin P, Lambert T. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob Agents Chemother. 2009;53(8):3579–3581. doi:10.1128/AAC.00072-09
  • Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269. doi:10.1038/NRMICRO3432
  • Hozzari A, Behzadi P, Kerishchi Khiabani P, Sholeh M, Sabokroo N. Clinical cases, drug resistance, and virulence genes profiling in Uropathogenic Escherichia coli. J Appl Genet. 2020;61(2):265–273. doi:10.1007/S13353-020-00542-Y
  • Chmielarczyk A, Wójkowska-Mach J, Romaniszyn D, et al. Mode of delivery and other risk factors for Escherichia coli infections in very low birth weight infants. BMC Pediatr. 2014;14(1). doi:10.1186/1471-2431-14-274
  • Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41(3):252–275. doi:10.1093/FEMSRE/FUX013
  • Poirel L, Madec J-Y, Lupo A, et al. Antimicrobial Resistance in Escherichia coli. Microbiol Spectr. 2018;6(4). doi:10.1128/MICROBIOLSPEC.ARBA-0026-2017
  • World Health Organization. WHO/IFPMA Workshop on Counterfeit Drugs (1992): Geneva, W. H. O. D. of D. M. and Policies, and I. F. of P. M. Associations, Counterfeit Drugs: Report of a WHO/IFPMA Workshop. Geneva PP – Geneva: World Health Organization; 1992.
  • Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013;57(10):4605–4607. doi:10.1128/AAC.01277-13
  • Poirel L, Thomas ILE, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum␤lactamase, and the class 1 integron In 52 from Klebsiella pneumoniae. Antimicrob Agents Chemother. 2000;44(3):622–632. doi:10.1128/AAC.44.3.622-632.2000
  • Wachino J, Doi Y, Yamane K, et al. Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class A␤lactamase, GES-3, in a neonatal intensive care unit in Japan. Antimicrob Agents Chemother. 2004;48(6):1960–1967. doi:10.1128/AAC.48.6.1960
  • Weldhagen GF, Poirel L, Nordmann P. MINIREVIEW ambler class A extended-spectrum␤lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother. 2003;47(8):2385–2392. doi:10.1128/AAC.47.8.2385
  • Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In 52 from Klebsiella pneumoniae. Antimicrob Agents Chemother. 2000;44(3):622 LP– 632.
  • Dubois V, Poirel L, Marie C, Arpin C, Nordmann P, Quentin C. Molecular characterization of a novel class 1 integron containing bla(GES-1) and a fused product of aac3-Ib/aac6’-Ib’ gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46(3):638–645. doi:10.1128/AAC.46.3.638-645.2002
  • Ambler RP, Coulson AFW, Frère JM, et al. A standard numbering scheme for the class A β -lactamases. Biochem J. 1991;276(Pt 1):269–270. doi:10.1042/BJ2760269
  • Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother. 2001;45(9):2598–2603. doi:10.1128/AAC.45.9.2598-2603.2001
  • Lévesque C, Brassard S, Lapointe J, Roy PH. Diversity and relative strength of tandem promoters for the antibiotic-resistance genes of several integrons. Gene. 1994;142(1):49–54. doi:10.1016/0378-1119(94)90353-0